Read our Recent Headlines


December 7 Biotech Update

The market can always surprise and I was surprised yesterday with the sector strength. The broader market did better than I expected but the sector clearly outperformed. It is only.

December 6 Biotech Update

China is back in the news and for good or ill, the sector fundamentals do not matter. Right now it is all about China and the broader market will pull.

December 4 Biotech Update

Yesterday was a good day but not as broad based as one would have hoped. Today will be telling in that the confusion over the China “trade deal” has only.

December 3 Biotech Update

It is certainly a great start to the week with generally good news from ASH, merger Monday, and easing trade tensions. If we do not get a gap and run.

November 29 Biotech Update

We are at an interesting place for the sector. The XBI is approaching the upper end of the downtrend, which has been acting as resistance. I am not totally convinced.

November 28 Biotech Update

Yesterday as a bad day for the sector as it was red with a positive broader market backdrop. To be fair it was a rather odd day in the sector.

November 26 Biotech Update

After a nice long holiday break, I figured there might be some more news to start the week but apparently not. The sector is off to a good start but.

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!